MiR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1

Y. Iwagami, H. Eguchi, H. Nagano, H. Akita, N. Hama, H. Wada, K. Kawamoto, S. Kobayashi, A. Tomokuni, Y. Tomimaru, M. Mori, Y. Doki

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background:Gemcitabine-based chemotherapy is the standard treatment for pancreatic cancer. However, the issue of resistance remains unresolved. The aim of this study was to identify microRNAs (miRNAs) that govern the resistance to gemcitabine in pancreatic cancer.Methods:miRNA microarray analysis using gemcitabine-resistant clones of MiaPaCa2 (MiaPaCa2-RGs), PSN1 (PSN1-RGs), and their parental cells (MiaPaCa2-P, PSN1-P) was conducted. Changes in the anti-cancer effects of gemcitabine were studied after gain/loss-of-function analysis of the candidate miRNA. Further assessment of the putative target gene was performed in vitro and in 66 pancreatic cancer clinical samples.Results:miR- 320c expression was significantly higher in MiaPaCa2-RGs and PSN1-RGs than in their parental cells. miR-320c induced resistance to gemcitabine in MiaPaCa2. Further experiments showed that miR-320c-related resistance to gemcitabine was mediated through SMARCC1, a core subunit of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex. In addition, clinical examination revealed that only SMARCC1-positive patients benefited from gemcitabine therapy with regard to survival after recurrence (P=0.0463).Conclusion:The results indicate that miR-320c regulates the resistance of pancreatic cancer cells to gemcitabine through SMARCC1, suggesting that miR-320c/SMARCC1 could be suitable for prediction of the clinical response and potential therapeutic target in pancreatic cancer patients on gemcitabine-based therapy.

Original languageEnglish
Pages (from-to)502-511
Number of pages10
JournalBritish journal of cancer
Volume109
Issue number2
DOIs
Publication statusPublished - Jul 23 2013

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'MiR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1'. Together they form a unique fingerprint.

  • Cite this

    Iwagami, Y., Eguchi, H., Nagano, H., Akita, H., Hama, N., Wada, H., Kawamoto, K., Kobayashi, S., Tomokuni, A., Tomimaru, Y., Mori, M., & Doki, Y. (2013). MiR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. British journal of cancer, 109(2), 502-511. https://doi.org/10.1038/bjc.2013.320